© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Raritan, NJ-Ortho-McNeil Pharmaceutical has received FDA approval to market levofloxacin (Levaquin) for the treatment of chronic bacterial prostatitis caused by Escherichia coli, Enterococcus faecalis, or Staphylococcus epidermidis.